D-dimer In Patients With atRial Fibrillation rEceiving antiCoagulation Therapy

This is a sigle-center, prospective study to evaluate the role of D-Dimer testing in patients with atrial fibrillation receiving Dabigatran or warfarin anticoagulation therapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atrial Fibrillation Arrhythmias, Cardiac Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Heart Diseases Ischemic Stroke Nervous System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Stroke Strokes Thrombotic Thrombotic Stroke Vascular Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

WAHH

Wuhan, Hubei, 430000, China

About this study

Patients with atrial fibrillation receiving Dabigatran or warfarin anticoagulation therapy was screened and signed to two group: Dabigatran group and Warfarin group. D-dimer test was analyzed before and 3 months after anticoagulation starting specificly. Patients were followed-up for at least 12 months,and clinical outcomes, including thrombotic events major bleeding events and all-cause deaths were recorded during follow-up period.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Non-valvular atrial fibrillation
Receiving oral anticoagulation therapy and have good compliance

Exclusion criteria

Life expectancy less than 1 year
Thrombosis or major bleeding history within 3 months
Refusal to Participate

Treatment and study plan

Dabigatran Etexilate 110mg

Drug

Dabigatran Etexilate 110mg, BID

Other names: Pradaxa

Warfarin sodium

Drug

Target INR:1.6-3.0

Primary outcomes

Cardiovascular events

Time frame: 12 months

Thrombotic events, cardiovascular deaths, major bleeding events

Sponsors and collaborators

Lead sponsor

Wuhan Asia Heart Hospital

Other

Registry information

Official study title

The Role of D-dimer in Patients With Atrial Fibrillation Receiving Anticoagulation Therapy

Acronym: DIRECT

Important dates

Study start: 2015
Primary completion: 2017
Study completion: 2017
First posted: Sep 12, 2017
Registry last updated: Sep 12, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed